Northern Trust Corp Has $9.34 Million Stock Position in Certara, Inc. (NASDAQ:CERT)

Northern Trust Corp increased its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 14.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 877,010 shares of the company's stock after purchasing an additional 108,038 shares during the quarter. Northern Trust Corp owned approximately 0.54% of Certara worth $9,340,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brown Brothers Harriman & Co. raised its stake in Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after acquiring an additional 1,487,998 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Certara by 169.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after acquiring an additional 1,253,385 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in Certara during the fourth quarter worth $11,542,000. Teacher Retirement System of Texas raised its stake in Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock worth $48,542,000 after acquiring an additional 557,348 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Certara during the fourth quarter worth $3,628,000. 73.96% of the stock is owned by institutional investors.

Certara Price Performance

Shares of NASDAQ:CERT traded down $0.06 during midday trading on Friday, reaching $11.42. The company's stock had a trading volume of 1,121,254 shares, compared to its average volume of 1,329,043. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $17.76. The company has a market capitalization of $1.85 billion, a P/E ratio of -57.10, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business's fifty day simple moving average is $11.78 and its 200-day simple moving average is $11.76.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company's revenue was up 9.7% on a year-over-year basis. During the same period last year, the company earned $0.10 earnings per share. As a group, equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Robert W. Baird increased their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. William Blair restated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. Finally, Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.